Nurix Therapeutics (NRIX) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Climate Environment Environmental Escape Extreme Weather Forest Green Intensity Materials Nature Offset Package Packaging Pandemic Raw Materials Recycling Renewable Toxic Waste Access African American Asian Benefits Black California Consumer Privacy Act Charitable Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Pay Equity Pay for Performance Perquisites Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Societal Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Workers Workforce Anti-corruption Anticorruption Assessment Assurance Attorney General Attorneys General Audit Bonus Bribery Chronic Classified Classified Board Commitment Conflict of Interest Corporate Governance Corporate Purpose Corporate Social Responsibility Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Other Public Company Boards Oversee Oversight Perquisite Pledging Purpose R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Single Trigger Special Meeting Strategy Sustainability Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 5, 2022, Nurix Therapeutics, Inc. (the “Company”) held its virtual 2022 Annual Meeting of Stockholders exclusively online via live webcast (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 25, 2022 (the “Proxy Statement”). There were 38,626,649 shares of common stock present at the Annual Meeting in person or by proxy, which represented approximately 86% of the voting power of the shares of common stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company’s common stock were entitled to one vote for each share held as of the close of business on March 11, 2022.
The stockholders of the Company voted on the following proposals at the Annual Meeting:
1. To elect two Class II directors, each of whom is currently serving on the Company’s Board of Directors (the “Board”), each to serve a three-year term expiring at the Company’s 2025 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.
2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending November 30, 2022.
3. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
4. To approve, on a non-binding advisory basis, the frequency of future votes on the compensation of the Company’s named executive officers.
The final voting results for each of these proposals are detailed below.
Proposal 1. Election of Directors

Nominee	Votes For	Votes Withheld	Broker Non-Votes

Judith A. Reinsdorf, J.D.	35,374,752	45,271	3,206,626
Clay B. Siegall, Ph.D.	34,864,972	555,051	3,206,626

Each of the two nominees for director was elected to serve until the Company’s 2025 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.
Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm

Votes For		Votes Against		Abstentions		Broker Non-Votes

38,617,519		8,282		848		—

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending November 30, 2022.
Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers

Votes For		Votes Against		Abstentions		Broker Non-Votes

34,032,385		1,380,760		6,878		3,206,626

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
Proposal 4. Approval, on a Non-binding Advisory Basis, of the Frequency of Future Votes on the Compensation of the Company’s Named Executive Officers


One Year	Two Years	Three Years	Abstentions	Broker Non-Votes
35,025,154	9,034	379,470	6,365	—

The stockholders approved, on a non-binding advisory basis, that future advisory votes on the compensation of the Company’s named executive officers be held every year.
After taking into consideration the foregoing voting results and the Board’s prior recommendation in favor of an annual advisory stockholder vote on the compensation of the Company’s named executive officers, the Board has determined to hold future advisory votes on the compensation of the Company’s named executive officers every year until the next required non-binding advisory vote on the frequency of future votes on the compensation of the Company’s named executive officers.